European Leukemia Trial Registry
Trial: RAS-AZIC (OSHO #083)

More Details
Title Phase I/II Trial in patientes > 60 years with AML with Azacitidine and Chemotherapy
Scientific Title Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO)
Short Title RAS-AZIC (OSHO #083)
Trialgroup OSHO
Type of Trial multicentric
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age > 60 years
Status No longer recruiting
Start of Recruitment 31.08.2012
Leader Al-Ali, PD Dr. med., Haifa Kathrin
Contactperson

Biometrics
Krahl, Dr., Rainer

Coordinating Investigator Germany
Al-Ali, PD Dr. med., Haifa Kathrin
Tel: +49 (0)345 557-4959
Fax: +49 (0)345 557-2950
Email: haifa.al-ali@uk-halle.de
Homepage: www.medizin.uni-halle.de/onkologie

Centre of Trial Universitätsklinikum Leipzig
Shortprotocol Shortprotocol
created 09.09.2014 Johannes Kraus
changed 19.01.2017 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org